Scholars Central

Review articlePublished 8 Jul 2016

New-generation triazole antifungal drugs: review of the Phase II and III trials

Authors: Corrado Girmenia, Erica Finolezzi

Clinical Investigation

Volume 1 · Issue 11 · Pages 1577

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

In this article, the pharmacological, microbiological and clinical development progress from Phase II and III clinical trials with the new generation triazoles albaconazole, isavuconazole, posaconazole, ravuconazole and voriconazole are reviewed. These drugs exhibit a favorable toxicity profile and possess high activity against resistant and emerging fungal pathogens. Pharmacokinetic may be affected by variability in metabolism and/or gastrointestinal absorption. Only voriconazole and posaconazole have been adequately investigated and are now indicated in the treatment and prophylaxis of invasive fungal diseases. Other triazoles; albaconazole, isavuconazole and ravuconazole are under development; therefore, their future use is unknown.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Investigation
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Corrado Girmenia”
  • BylineArticles whose byline prints “Erica Finolezzi”